Search - tctmd.com

Displaying 41 - 60 of 71

Sort: Relevancy | Date

News Daily News

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

Michael O'Riordan

January 12, 2021

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

News Daily News

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

L.A. McKeown

August 31, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Todd Neale

February 07, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Caitlin E. Cox

January 08, 2018

Advertisement

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

GATEWAY at 3 Years: Bariatric Surgery Continues to Reduce Need for Antihypertensive Drugs

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Most Stable Angina Patients Not Taking First-line Meds

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Ticagrelor: Better Platelet Blockade Post-TAVR?

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content